• Journal of Radiopharmaceuticals and Molecular Probes
• /
• v.7 no.2
• /
• pp.79-84
• /
• 2021

Radiopharmaceuticals are important for tumor diagnosis and therapy. To deliver a radiotracer at the desired target excluding non-targeted tissues is difficult The development of a targeted tracer that has a good clearance profile while maintaining high biostability and biocompatibility is key to optimizing its biodistribution and transport across biological barriers. Improving the hydrophilicity of radiotracers by PEGylation can reduce serum binding, allowing the tracer to circulate without retention and reducing its affinity for non-targeted tissues. In this study, we synthesized a new benzamido tracer (SnBz-PEG₃₆) with the introduction of a low molecular weight polyethylene glycol unit (PEG₃₆, ~2,100 Da). The tumor targeting efficiency and biodistribution of [¹³¹I]-Bz-PEG₃₆ or radiotracer-loaded liposomes were evaluated after their administration to normal mice or mouse tumor models including CT26 (xenograft) and 4T1 (xenograft and orthotopic). Most of the radiotracer was cleared out rapidly (1-24 h post-administration) through the kidney and there was little tumor uptake.